# WHO Biological Reference Standards In vitro diagnostic devices

- Summary of the 2<sup>nd</sup> Meeting of the WHO CC -

Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical Policies Department Health Systems and Services



## Biological Standardization (\*) Constitutional responsibility

- WHO is mandated by it's Member States to "...develop, establish and promote international standards for biological products."
- In practice, biological products cover
  - » Vaccines
  - » Blood and blood products
  - » In vitro biological diagnostic devices
  - » Other biological products
- \*) Expert Committee for Biological Standardization



### WHO Biological Reference Standards

- Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004): Annex 2, WHO TRS, No 932, 2005
- Report of the WHO Consultation on Global Measurement Standards and their use in the in vitro biological diagnostic field. WHO Geneva, June 2004:

www.who.int/bloodproducts/ivd/infectious markers

# WHO Biological Reference Preparations (www.who.int/bloodproducts\*)

- Nucleic Acid Technology:
  - HBV/HCV/HIV/Parvovirus/HAV (IS)
  - HIV genotype reference panel
- Immunoassays:
  - HBsAg; Anti-HBs; Anti-HBc
  - HIV p24 antigen
  - Anti-HIV subtype reference panel
- vCJD reference materials
- Blood grouping reagents
- Platelets immunology
- Blood Coagulation disorders







#### WHO IVD Standardization 2<sup>nd</sup> WHO CC\* Meeting: 17-19 February 2009

- Follow-up from the WHO CC Meeting in 2007
- Coordinate needs/priorities with WHO programs
- Discuss priority projects: WHO Biological Reference
   Preparations to optimally support global public health
- Update the strategic plan established in 2007
- Strengthen collaboration (WHO CC-Network model)

\*WHO CCs for Biological Standards & Standardization: CBER/FDA, USA; NIBSC, UK; PEI, Germany



### **Priority Projects – Parasites**

Preparation	Proposed Standard	Coordinator	Next steps & Decisions
Anti- <i>T. cruzi</i> antibody panel	Reference preparations under development	S. Rijpkema; A. Luquetti; M.Otani, C. Guzman- Bracho	Characterization of the candidate materials in process: Mexico ( <i>T. cruzi</i> I) and Brazil ( <i>T. cruzi</i> II). Collaborative Study 2010 <a href="http://www.who.int/bloodproducts/ref_materials/WHO_Report_1st_Chagas_BRP_consultation_7-2007_final.pdf">http://www.who.int/bloodproducts/ref_materials/WHO_Report_1st_Chagas_BRP_consultation_7-2007_final.pdf</a>
Anti- <i>Plasmodium</i> spec.	New Ref. Panel (new proposal)	S. Kumar, CBER P. Corran, NIBSC	Reference panel (falciparum, malariae, vivax) to validate blood donor screening assays (aiming to detect multi-species infections)
Anti- Toxoplasma (IgM)	Replacement of current IS (TOXM)	S. Rijpkema, NIBSC	Current standard does not distinguish between IgG and IgM. Influence on the IU values. Effort to make an IgM-purified material



## **Priority Projects – HIV**

Preparation	Proposed Standard	Coordinator	Next steps & Decisions
HIV-1 RNA genotype panel	2 <sup>nd</sup> Ref Panel; under development	H. Holmes, NIBSC/ I. Hewlett, CBER	Major pandemic strains (A, C), unusual subtypes (G, H, J, K, group O) and wider range of CRFs; max. 12 panel members; heat inactivation; lyophilization; collaborative study in process; report to ECBS 2010
HIV-2 RNA	1st IS, Proposal for establishment at ECBS 2009	C. Morris, H. Holmes, NIBSC; I. Hewlett, CBER	Collaborative study completed; Report to ECBS 2009



#### Priority Projects – Hepatitis viruses

Preparation	Proposed Standard	Coordinator	Next steps & Decisions

Reference Panel.

M. Chudy, PEI

NAT panel: 15 member; genotypes

collaborative study 2009/2010

Two candidate materials available:

HBV genotype panel: NAT

proposed for establishment

M. Nübling, PEI

A-G; collaborative study in process; report to ECBS 2009

tests HBV genotype

panel: HBsAg

HCV core Ag

tests

Reference Panel under

**ECBS 2009** 

M. Chudy, PEI M. Nübling, PEI HBsAg panel: 15 member; genotypes A-H; pilot study (Iyo);

development New proposal for development to

PEI

genotype 1 and 3 preparations (first one to calibrate in IU, the other show commutability) World Health Organization

8 Blood Products & related Biologicals: SoGAT, 28 May 09

### **Priority Projects – Parvovirus and Dengue**

Preparation	Proposed Standard	Coordinator	Next steps & Decisions
B19V DNA genotype panel	Reference Panel, proposed for establishment	P. Minor, NIBSC S. Baylis, PEI Mei-ying Yu, CBER	Four-member panel: genotypes 1, 2, 3 and negative plasma pool; collaborative study completed (33 labs); report to ECBS 2009
DENV RNA	DENV 1-4 NAT Ref Panel; New proposal for development to	M. Rios, CBER	Selection of candidate materials: access to viral isolates acquired from infected humans;



**ECBS 2009** 

### **Priority Projects – Herpes viruses**

Preparation	Proposed Standard	Coordinator	Next steps & Decisions
CMV DNA	1st IS: proposed study report ECBS 2010	J. Fryer, NIBSC	CMV strain Merlin propagated in cell culture; collaborative study will evaluate the material in parallel with strain AD169 and

J. Fryer,

NIBSC

**ECBS 2010** 

1st IS:

proposed

study report

EBV DNA

EBV strain B95-8 propagated in

cell culture; collaborative study

in parallel with two other EBV-

purified Merlin DNA;

positive cells;

# Other projects discussed (further consultation or information needed)

- Anti-HTLV-1/2 antibody panel
- Anti-HHV-8 antibodies and HHV-8 DNA
- Anti-CMV antibody standards (IgG, IgM)
- Blood-borne bacteria reference panel
- FLAVI, ARTHROPOD-BORNE HEMORRHAGIC VIRUSES:
   WNV RNA panel; Anti-DENV (IgM); Chikungunya virus; Japanese
   Encephalitis
- HEPATITIS VIRUSES: HDV RNA; HEV RNA; Anti-HCV mono-specific antibodies
- PARASITES: Anti-T. brucei spec. (African trypanosomiasis); Anti-Babesia spec. antibody panel;
- POLYOMA/PAPLILLOMA VIRUSES: BK DNA and JC DNA
- TSE BLOOD REFERENCE MATERIALS



# WHO Biological Reference Preparations WHO Catalogue

Web site address:

http://www.who.int/bloodproducts

